MTOR and prostate neoplasm: Their results demonstrated that Luteolin was able to significantly inhibit VEGF-stimulated endothelial cell proliferation, chemotactic migration, invasion, tube formation, and angiogenesis by targeting the VEGFR-2-regulated Akt/ERK/mammalian target of rapamycin (mTOR)/P70S6K/MMPs pathway that caused the suppression of prostate tumor growth and angiogenesis.